High Growth Tech Leads These 3 Top Stocks with Promising Potential

ALNY Stock  USD 259.13  12.86  5.22%   
Slightly above 69 percent of all Alnylam Pharmaceuticals' investors are curious in acquiring. The analysis of the overall investor sentiment regarding Alnylam Pharmaceuticals suggests that a large number of traders are confidant. Alnylam Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Alnylam Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
As global markets navigate a mixed economic landscape, characterized by declining consumer confidence and fluctuations in major indices, the technology sector continues to capture attention with its potential for high growth. In this environment, identifying promising stocks often involves looking at companies that demonstrate innovation and adaptability to changing market conditions, which are key factors in thriving amid economic uncertainties.

Read at finance.yahoo.com
Yahoo News
  

Alnylam Pharmaceuticals Current Investor Sentiment

Panic Vs Confidence

69

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Alnylam Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Alnylam Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Alnylam Pharmaceuticals Historical Investor Sentiment

Investor biases related to Alnylam Pharmaceuticals' public news can be used to forecast risks associated with an investment in Alnylam. The trend in average sentiment can be used to explain how an investor holding Alnylam can time the market purely based on public headlines and social activities around Alnylam Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Alnylam Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Alnylam Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Alnylam Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals Maximum Pain Price Across March 21st 2025 Option Contracts

Alnylam Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Alnylam Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Alnylam Pharmaceuticals' options.

Alnylam Pharmaceuticals Fundamental Analysis

We analyze Alnylam Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alnylam Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alnylam Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Outstanding

Shares Outstanding Comparative Analysis

Alnylam Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Alnylam Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alnylam Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Alnylam Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Alnylam Pharmaceuticals Related Equities

UTHRUnited Therapeutics   2.99   
0%
54.0%
INCYIncyte   2.09   
0%
38.0%
HALOHalozyme Therapeutics   2.03   
0%
36.0%
WVEWave Life   1.46   
0%
26.0%
BMRNBiomarin Pharmaceutical   1.22   
0%
22.0%
BPMCBlueprint Medicines   0.59   
0%
10.0%
KRYSKrystal Biotech   0.42   
0%
7.0%
APLSApellis Pharmaceuticals   0.20   
0%
3.0%
EXELExelixis   0.03   
0%
1.0%
MDGLMadrigal Pharmaceuticals   0.00   
0%
0%
AMLXAmylyx Pharmaceuticals   0.00   
0%
0%
RAREUltragenyx   0.00   
0%
0%
DAWNDay One   0.88   
16.0%
0%
PRQRProQR Therapeutics   5.49   
100.0%
0%

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.